

NEW RETAILER TO STOCK MUTE IN 3000 NEW PHARMACIES ACROSS THE USA

KEY HIGHLIGHTS:

- Rhinomed opens a new distribution arrangement with one of the US's largest pharmacy retailers.
- Mute to be core ranged in an additional 3000 pharmacies in the USA.
- Stock expected to be on shelf from July/August onwards.

May 28 2018, Melbourne, Australia.

Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has entered into a new distribution agreement with, and received an initial order for stock from a new retailer. The retailer is one of America's largest pharmacy retailers.

These purchase orders confirm that Mute will be stocked on the shelves of an additional 3000 pharmacies across the USA. This agreement grows Rhinomeds' global store base to over 10,000 stores across three continents.

There are limitations under the order arrangements on the disclosure that Rhinomed can currently provide to investors, as a guide it can provide the following information:

- Details regarding the identity of the retailer will be announced in line with stock appearing on shelf in the USA in July/August.
- The company has now received the initial opening order of 6000 units and expects more orders to follow.
- Revenues from this new retail channel are not expected to impact the business until FY19 Q2 at the earliest.
- The agreement has no fixed term and can be terminated by either party.
- Pricing details remain confidential.

Rhinomed CEO Michael Johnson commented, "*This is a critical step in our strategy of ensuring that our retail footprint increases in the significant American market. Rhinomed is continuing to demonstrate that Australian companies are not only great innovators but can also successfully commercialize innovation in one of the most competitive markets in the world - the North American Consumer Health market.*"

R H I N O M E D

MAKE EVERY BREATH COUNT

While the supplier agreement and receipt of an initial order creates potential new market opportunities for Rhinomed and increases the retail reach of the product in the USA it is not an assurance of ongoing or future retail sales. It is too early to accurately forecast the likely long term impact of revenues from the Agreement on Rhinomed financial results.

Media Enquiries

Michael Johnson, CEO & Director

+61 (03) 8416 0900

mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo and @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

About the Mute™

Mute™ is a unique nasal respiratory technology that has been found to reduce the volume and frequency of snoring in 75% of users. Mute is easy to use, drug free and fits discreetly inside the nose. Designed to give snoring the silent treatment and made from ultra-soft polymers, Mute gently expands each nostril to increase the volume of air in each breath. By doing so, Mute encourages nasal breathing and reduces the need to open the mouth during sleep, factors critical to a reduction in snoring and better sleep quality. For more information or to purchase online, visit www.mutesnoring.com

Forward Looking Statements

This release includes forward looking statements. Often, but not always, forward looking statements can generally be identified by the use of forward looking words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "continue", and "guidance", or other similar words and may include, without limitation statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs of production outputs. Forward looking statements in this release include, but are not limited to, the potential opportunity created by the new distribution channel.

Entry into a distribution arrangement does not guarantee that any particular volume of sales revenue will result. Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance and achievements to differ materially from any future results, performance or achievements. Relevant factors may include, but are not limited to, consumer preferences, competing products, foreign exchange fluctuations, the counterparty's acts and omissions, increased costs, changes to government legislation and many other factors. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove to be correct, or that the Company's business or operations will not be impacted in any material manner by these or other factors not foreseen or foreseeable by the Company or management or that are beyond the Company's control. Accordingly, readers are cautioned not to place undue reliance on forward looking statements.